DREAMM Trial Update - Blenrep in Myeloma Trials | Natalie Callander, MD | ASH 2021

DREAMM Trial Update - Blenrep in Myeloma Trials | Natalie Callander, MD | ASH 2021

DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patientsПодробнее

DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patients

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trialsПодробнее

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials

Natalie Callander, MD on the new GSK Antibody Drug Conjugate Immunotherapy — IMW 2019Подробнее

Natalie Callander, MD on the new GSK Antibody Drug Conjugate Immunotherapy — IMW 2019

DREAMM-2 & DREAMM-5: belantamab mafodotin for myelomaПодробнее

DREAMM-2 & DREAMM-5: belantamab mafodotin for myeloma

Vaccinations & iStopMM Trial | Natalie Callander, MD | IMS 2022Подробнее

Vaccinations & iStopMM Trial | Natalie Callander, MD | IMS 2022

The current state of MRD-based therapy for myelomaПодробнее

The current state of MRD-based therapy for myeloma

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma

MRD highlights from the IMW meetingПодробнее

MRD highlights from the IMW meeting

Dr. Cohen on the DREAMM-2 TrialПодробнее

Dr. Cohen on the DREAMM-2 Trial

The DREAMM-5 PLATFORM trialПодробнее

The DREAMM-5 PLATFORM trial

Natalie Callander, MD, Discusses Melflufen Approval for Relapsed/Refractory Multiple MyelomaПодробнее

Natalie Callander, MD, Discusses Melflufen Approval for Relapsed/Refractory Multiple Myeloma

Case Study - Anti-BCMA CAR-T - a unique late term side effect | Oliver Van Oekelen | ASH 2021Подробнее

Case Study - Anti-BCMA CAR-T - a unique late term side effect | Oliver Van Oekelen | ASH 2021

The promise of belantamab mafodotin for the treatment of multiple myelomaПодробнее

The promise of belantamab mafodotin for the treatment of multiple myeloma

DREAMM-2: update on belantamab mafodotin in R/R myelomaПодробнее

DREAMM-2: update on belantamab mafodotin in R/R myeloma

Results of DREAMM-4: safety and efficacy of belantamab mafodotin with pembrolizumab in R/R myelomaПодробнее

Results of DREAMM-4: safety and efficacy of belantamab mafodotin with pembrolizumab in R/R myeloma

Dara-KRd, transplant, and MRD response-adapted treatment in newly diagnosed myelomaПодробнее

Dara-KRd, transplant, and MRD response-adapted treatment in newly diagnosed myeloma

DREAMM‑3 - Blenrep (Belmaf) Vs PomDex For Relapsed/Refractory Myeloma | Katja Weisel, MD | ASCO 2023Подробнее

DREAMM‑3 - Blenrep (Belmaf) Vs PomDex For Relapsed/Refractory Myeloma | Katja Weisel, MD | ASCO 2023

A real-world analysis of belantamab mafodotin in patients with R/R multiple myelomaПодробнее

A real-world analysis of belantamab mafodotin in patients with R/R multiple myeloma